GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ignyta Inc (NAS:RXDX) » Definitions » Debt-to-EBITDA

Ignyta (Ignyta) Debt-to-EBITDA : -0.28 (As of Sep. 2017)


View and export this data going back to 2014. Start your Free Trial

What is Ignyta Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ignyta's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.00 Mil. Ignyta's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $29.99 Mil. Ignyta's annualized EBITDA for the quarter that ended in Sep. 2017 was $-109.06 Mil. Ignyta's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2017 was -0.28.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ignyta's Debt-to-EBITDA or its related term are showing as below:

RXDX's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.3
* Ranked among companies with meaningful Debt-to-EBITDA only.

Ignyta Debt-to-EBITDA Historical Data

The historical data trend for Ignyta's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ignyta Debt-to-EBITDA Chart

Ignyta Annual Data
Trend Aug12 Aug13 Dec14 Dec15 Dec16
Debt-to-EBITDA
- - -0.53 -0.47 -0.32

Ignyta Quarterly Data
Nov12 Feb13 May13 Aug13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 -0.29 -0.20 -0.28 -0.28

Competitive Comparison of Ignyta's Debt-to-EBITDA

For the Biotechnology subindustry, Ignyta's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ignyta's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ignyta's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ignyta's Debt-to-EBITDA falls into.



Ignyta Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ignyta's Debt-to-EBITDA for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 31.117) / -96.947
=-0.32

Ignyta's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 29.994) / -109.056
=-0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2017) EBITDA data.


Ignyta  (NAS:RXDX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ignyta Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ignyta's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ignyta (Ignyta) Business Description

Traded in Other Exchanges
N/A
Address
Ignyta is an oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. The integrated therapeutic segment aims to discover, develop, and commercialize molecularly targeted therapies. The companion diagnostic segment aims to pair the discovered therapies with biomarker-based companion diagnostics to precisely identify, at the molecular level, patients likely to have good results. The company's portfolio includes compounds to treat adult patient populations for solid tumors, pediatric patients with advanced solid tumor malignancies, and patients with superficial and nodular basal cell carcinoma.
Executives
James L Freddo director 3115 MERRYFIELD ROW, SAN DIEGO CA 92121
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Pratik S Multani officer: Chief Medical Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Jonathan E Lim director, 10 percent owner, officer: President, CEO & Director 11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jacob Chacko officer: Chief Financial Officer C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Igor Bilinsky officer: GM, Immuno-Oncology/SVP Sp Ops C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Matthew Onaitis officer: General Counsel and Secretary C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Adrian Senderowicz officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024

Ignyta (Ignyta) Headlines

From GuruFocus

Steven Cohen Dives Deeper Into Health Care

By Graham Griffin Graham Griffin 03-23-2021